Bilimsel çalışmalar

Prof. Dr. Gül Başaran

139 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. 2008P The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey molecular profiling in advanced cancers trial (TUMPACT)

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.1314 Açık erişimli tam metinKaynak: OpenAlex

  2. COVID Pandemisi Sürecinde Meme Kanserinde Antihormon Tedavi

    Türkiye Klinikleri COVID - 19, 2020

    Kaynak: OpenAlex

  3. Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

    Cancer Research, 2020

    DOI 10.1158/1538-7445.sabcs19-p5-11-19 Kaynak: OpenAlex

  4. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e13055 Kaynak: OpenAlex

  5. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

    Turkish Journal of Surgery, 2020

    DOI 10.5578/turkjsurg.4815 PMID 33015560 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  6. Yaşlı Hastalarda Meme Kanseri Tedavisine Yaklaşım

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Kaynak: OpenAlex

  7. APPROACH TO BREAST CANCER TREATMENT IN ELDERLY PATIENTS

    Turkiye Klinikleri eBooks, 2020

    DOI 10.5336/978-625-401-191-7_p77 Kaynak: OpenAlex

  8. Adjuvant Therapy for HER-2-Positive Early Breast Cancer

    Springer eBooks, 2019

    DOI 10.1007/978-3-030-16792-9_9 Kaynak: OpenAlex

  9. THE EFFECT OF HYPERTENSION THE TREATMENT OF DOXAZOSIN ON BENIGN PROSTATE HYPERPLASIA PATIENTS

    Urology Research and Practice, 2019

    Açık erişimli tam metinKaynak: OpenAlex

  10. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    Cancer Chemotherapy and Pharmacology, 2018

    DOI 10.1007/s00280-018-3712-7 PMID 30377778 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

    Annals of Oncology, 2018

    DOI 10.1093/annonc/mdy272.315 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  12. Türkiye’de Metastatik Meme Kanserinde HER2 hedefli tedavide Pertuzumab kullanımı erken dönem güvenlilik verileri

    Kocaeli Üniversitesi - AVESİS, 2018

    Kaynak: OpenAlex

  13. Türkiye’xxde metastatik meme kanserinde Her2 hedefli tedavide pertuzumab kullanımı erken dönem güvenlilik verileri

    Kocaeli Üniversitesi - AVESİS, 2018

    Kaynak: OpenAlex

  14. Türkiye'de Metastatik Meme Kanserinde HER-2 Hedefli Tedavide Pertuzumab Kullanımının Erken Dönem Güvenlik Verileri

    Van Yüzüncü Yıl University Academic Data Management System, 2018

    Kaynak: OpenAlex

  15. Gebelik ve Meme Kanseri (TOG Meme ve Genç Araştırmacılar Grubu çalışması)

    Kocaeli Üniversitesi - AVESİS, 2018

    Kaynak: OpenAlex

  16. Cost of Treatment of HR+/HER2- Post Menopausal Advanced/Metastatic Breast Cancer Patients in Turkey

    Value in Health, 2016

    DOI 10.1016/j.jval.2016.03.1569 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  17. Adjuvant Therapy for HER2-Positive Early Breast Cancer

    Springer eBooks, 2016

    DOI 10.1007/978-3-319-26012-9_9 Kaynak: OpenAlex

  18. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

    Critical Reviews in Oncology/Hematology, 2015

    DOI 10.1016/j.critrevonc.2015.10.006 PMID 26603345 38 atıf (Europe PMC) Kaynak: OpenAlex

  19. Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e11589 Kaynak: OpenAlex

  20. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

    European Journal of Cancer, 2015

    DOI 10.1016/j.ejca.2015.10.012 PMID 26724641 36 atıf (OpenAlex) Kaynak: OpenAlex

  21. Mutation analysis of the BRCA1 and BRCA2 genes in Turkish patients with breast cancer.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e12536 Kaynak: OpenAlex

  22. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

    Meme sağlığı dergisi/Meme sağlığı dergisi, 2014

    DOI 10.5152/tjbh.2014.1904 PMID 28331673 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  23. Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.1.117 PMID 24528011 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  24. Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

    Europe PMC (PubMed Central), 2014

    PMID 24995112 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  25. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: Single institution experience.

    Journal of Clinical Oncology, 2014

    DOI 10.1200/jco.2014.32.15_suppl.e19503 2 atıf (OpenAlex) Kaynak: OpenAlex

  26. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

    Breast Cancer, 2013

    DOI 10.1007/s12282-013-0506-y PMID 24338610 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  27. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

    The Breast, 2013

    DOI 10.1016/j.breast.2013.07.048 PMID 23954396 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  28. Hipokalemik Paralizi ile Klinik Belirti Veren Adrenokortikal Karsinom Olgusu

    Acibadem University Open Access Repository, 2013

    Açık erişimli tam metinKaynak: OpenAlex

  29. 349 High Ki67 Values Are Significantly Correlated with Oncotype DX Scores

    European Journal of Cancer, 2012

    DOI 10.1016/s0959-8049(12)70415-x Kaynak: OpenAlex

  30. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.e16015 Açık erişimli tam metinKaynak: OpenAlex

  31. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

    Kocaeli Üniversitesi - AVESİS, 2012

    Kaynak: OpenAlex

  32. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer

    Biomarkers, 2012

    DOI 10.3109/1354750x.2012.738250 PMID 23116493 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  33. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK).

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e12007 Açık erişimli tam metinKaynak: OpenAlex

  34. Primary breast mantle cell lymphoma with atypical relapse patterns.

    PubMed, 2011

    PMID 21674874 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study.

    PubMed, 2011

    PMID 21766495 Açık erişimli tam metinKaynak: OpenAlex

  36. The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.

    PubMed, 2011

    PMID 22331719 3 atıf (Europe PMC) Kaynak: OpenAlex

  37. TÜRKİYE’xxDE MEME KANSERLİ HASTALARIN TANI VE TEDAVİ YÖNTEMLERİNE ULAŞIM HIZI ÇOK MERKEZLİ GÖZLEMSEL ÇALIŞMA.

    Dspace Repository (Marmara Üniversitesi), 2011

    2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  38. Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC).

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e18010 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  39. Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e14668 Açık erişimli tam metinKaynak: OpenAlex

  40. Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e11019 Açık erişimli tam metinKaynak: OpenAlex

  41. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.629 5 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  42. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e13079 1 atıf (OpenAlex) Kaynak: ORCID

  43. The impact of 21-gene recurrence score (RS) scores on treatment decisions: Retrospective evaluation in Turkish early-stage breast cancer (BC) patients.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e11042 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  44. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

    Medical Oncology, 2010

    DOI 10.1007/s12032-010-9463-x PMID 20306160 17 atıf (Europe PMC) Kaynak: OpenAlex

  45. Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

    Medical Oncology, 2010

    DOI 10.1007/s12032-010-9516-1 PMID 20390469 14 atıf (Europe PMC) Kaynak: OpenAlex

  46. 498 Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience

    European Journal of Cancer Supplements, 2010

    DOI 10.1016/s1359-6349(10)70519-x Açık erişimli tam metinKaynak: OpenAlex

  47. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?

    Journal of Clinical Oncology, 2010

    DOI 10.1200/jco.2010.29.0304 PMID 20606082 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  48. E7. Taxanes as adjuvant therapy for breast cancer

    European Journal of Cancer Supplements, 2010

    DOI 10.1016/s1359-6349(10)70011-2 Açık erişimli tam metinKaynak: OpenAlex

  49. Dalakta ve terminal ileumda gelişen malign melanom metastazı, cerrahi tedavi sonrası oluşan perineal metastaz: Olgu sunumu

    Kocaeli Üniversitesi - AVESİS, 2010

    Kaynak: OpenAlex

  50. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.

    PubMed, 2009

    PMID 19650184 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex